AV Laboratories is redefining the future of skincare by translating decades of advanced biotechnology research into ...

Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced the acceptance of an abstract for poster presentation at the ...

Phase 3 study is supported by the Coalition for Epidemic Preparedness Innovations to help strengthen global preparedness against a significant pandemic threat CAMBRIDGE, MA / ACCESS Newswire / April ...

Artists Earn a $1,000 Stipend While Inspiring Drug DiscoveryMADISON, Wis.--(BUSINESS WIRE)--Invenra, Inc., a biotechnology company pioneering multispecific antibody therapeutics, is requesting cancer ...

Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), today provided an update that Garda Therapeutics, Inc. (“Garda”) intends to commence the tender offer to acquire all outstanding ...

Signing of a two-year shareholder loan agreement for up to €6.0 million, of which €1.5 million paid upon signing, repayable in new shares representing up to 7.6% of the Company’s share capital or in ...

VANCOUVER, BC / ACCESS Newswire / April 21, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") announces the successful completion of a ...

LAFAYETTE, LA / ACCESS Newswire / April 21, 2026 / Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national provider of technology-enabled, home-based healthcare solutions and ...

Transaction Strengthens Balance Sheet and Accelerates Capital Recycling into Private Pay Senior Housing MURFREESBORO, TN / ACCESS Newswire / April 21, 2026 / National Health Investors, Inc. (NYSE:NHI) ...

Phase III METEOROID study met its primary endpoint in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)MOGAD is a rare autoimmune disease of the central nervous ...

Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Aquestive Therapeutics, Inc. (NASDAQ: AQST) securities between June 16, ...

New evidence for established standard-of-care therapies, with updates for LORBRENA® in ALK-positive metastatic non‑small cell lung cancer and a BRAFTOVI® regimen in a type of BRAF-mutant colorectal ...